PBA
LKFT

Paradigm Biocapital Advisors’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Paradigm Biocapital Advisors’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-167,824
Closed -$9.25M – 28
2021
Q4 		$9.25M Buy
+167,824
New +$8.76M 2.64% 16

Other funds holding LKFT

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Paradigm Biocapital Advisors's LKFT Position: Q1 2022 in Review

Paradigm Biocapital Advisors sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q1 2022, closing a stake of 167,824 shares — an estimated $9.25M sold.

Paradigm Biocapital Advisors first reported a position in LKFT in Q4 2021 and held it in 1 quarter. The position peaked at $9.25M in Q4 2021. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2022.

  • Paradigm Biocapital Advisors reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q1 2022 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 167,824 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2022, an estimated $9.25M.
  • Paradigm Biocapital Advisors first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2021 and held it in 1 quarter.
  • Paradigm Biocapital Advisors's Lakefront Biotherapeutics American Depositary Shares position peaked at $9.25M in Q4 2021.
  • 90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2022.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2022, filed 16 May 2022.